Inmune Bio Inc. Focuses on Cancer Treatment Development

Inmune Bio Inc., a clinical-stage biotechnology company based in La Jolla, California, continues to advance its mission of developing innovative medicines to treat cancer. As a key player in the health care sector, the company is dedicated to serving clients exclusively within the United States. With its primary listing on the Nasdaq stock exchange, Inmune Bio has been publicly traded since its Initial Public Offering (IPO) on February 4, 2019.

As of June 19, 2025, Inmune Bio’s stock closed at $6.38. Over the past year, the company’s stock has experienced significant fluctuations, reaching a 52-week high of $10.50 on February 4, 2025, and a 52-week low of $4.32 on December 19, 2024. Despite these variations, the company maintains a market capitalization of approximately $168 million.

Inmune Bio’s financial metrics reflect the challenges often faced by companies in the biotechnology sector. The company’s price-to-earnings ratio stands at -3.71, indicating that it is not currently generating profits. This is not uncommon for clinical-stage biotech firms, which typically invest heavily in research and development before achieving commercial success.

The company’s focus remains on its pipeline of cancer treatments, aiming to bring new therapeutic options to patients. For more detailed information about Inmune Bio’s operations, offerings, and future plans, stakeholders and interested parties are encouraged to visit their website at www.inmunebio.com .

As Inmune Bio continues its journey in the competitive biotechnology landscape, its commitment to innovation and patient care remains at the forefront of its strategic objectives.